# RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

> **NCT06121297** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cabaletta Bio** · enrollment: 28 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Lupus Nephritis

## Interventions

- **BIOLOGICAL:** CABA-201
- **BIOLOGICAL:** CABA-201

## Key facts

- **NCT ID:** NCT06121297
- **Lead sponsor:** Cabaletta Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-16
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06121297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06121297, "RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06121297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*